← back to search

Joseph F. Merola

Southwestern Medical Center · US
Area of research
Immunology · Rheumatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments, Rheumatoid Arthritis Research and Therapies, and Dermatology and Skin Diseases.
h-index
53
citations
12,814
works
716
NIH funding
primary concept
email

Recent publications

Psoriasis
Nature Reviews Disease Primers 2025cited by 104position: lastdoi
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
Nature Reviews Rheumatology 2025cited by 12position: middledoi
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
Nature Medicine 2025cited by 10position: lastdoi
Defining On-Treatment Remission in Plaque Psoriasis
JAMA Dermatology 2025cited by 7position: middledoi
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms
Dermatology and Therapy 2025cited by 2position: firstdoi
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council
JAMA Dermatology 2024cited by 54position: middledoi
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Journal of the American Academy of Dermatology 2024cited by 18position: middledoi
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis
JAMA Dermatology 2024cited by 16position: middledoi
Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology 2024cited by 15position: middledoi
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Dermatology and Therapy 2024cited by 14position: firstdoi
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Lara D. Veeken 2024cited by 12position: lastdoi
Psoriatic arthritis: A comprehensive review for the dermatologist part I: Epidemiology, comorbidities, pathogenesis, and diagnosis
Journal of the American Academy of Dermatology 2024cited by 10position: lastdoi
Psoriatic arthritis: A comprehensive review for the dermatologist–Part II: Screening and management
Journal of the American Academy of Dermatology 2024cited by 9position: lastdoi
Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study
Journal of the American Academy of Dermatology 2024cited by 1position: firstdoi
GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease
The Journal of Rheumatology 2024cited by 1position: lastdoi
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting
The Journal of Rheumatology 2024cited by 1position: middledoi
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Journal of the American Academy of Dermatology 2023cited by 41position: middledoi
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Journal of the American Academy of Dermatology 2023cited by 25position: firstdoi
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
British Journal of Dermatology 2023cited by 21position: firstdoi
Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA Survey
The Journal of Rheumatology 2023cited by 5position: middledoi
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting
The Journal of Rheumatology 2023cited by 2position: middledoi
332 Improvement in symptoms of atopic dermatitis (AD) and AD-related quality of life with dupilumab treatment in adults: 24-week results of the DUPISTAD study
British Journal of Dermatology 2023cited by 0position: firstdoi
335 Improvement in sleep quality, anxiety and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment
British Journal of Dermatology 2023cited by 0position: firstdoi
43006 Dupilumab Improves Sleep in Adults with Moderate-to-Severe Atopic Dermatitis over 24 Weeks
Journal of the American Academy of Dermatology 2023cited by 0position: firstdoi
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Journal of the European Academy of Dermatology and Venereology 2022cited by 183position: lastdoi
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
The Lancet 2022cited by 156position: firstdoi
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
British Journal of Dermatology 2022cited by 74position: middledoi
Does biologic therapy impact the development of PsA among patients with psoriasis?
Annals of the Rheumatic Diseases 2022cited by 66position: middledoi
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
BMJ Open 2022cited by 51position: middledoi
Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
Dermatology and Therapy 2022cited by 14position: firstdoi

Grants

Acquisition of High-Impact Computational Resources for Cyber-Enabled Research and Education
NSF0741927$462,3962008–2012PIRePORTER
Upgrade of 300 MHz Solid State NMR
NSF0541764$278,3002006–2009PIRePORTER
MRI: Development of a Colloidal Force-Distance-Adsorption Apparatus for Particle Science Research and Education
NSF0216129$395,0002002–2006PIRePORTER
Proximal Adsorption in Colloidal Systems
NSF0203987$311,0002002–2006PIRePORTER
Chemistry of Iridium Hydride Complexes Synthesized by Addition of Non-Metal Hydrides
NSF9214027$267,0001992–1997PIRePORTER
Synthesis and Study of Iridium Hydride Complexes Created by Addition of E-H Molecules(E = H,B,C,N,O)
NSF9022444$87,5001991–1993PIRePORTER

Frequent collaborators

Alice B. Gottlieb · Yale University17 papers (2013–2025)April W. Armstrong · Central Dermatology13 papers (2018–2025)Lourdes M. Pérez-Chada · Amgen (United States)9 papers (2018–2024)Philip J. Mease · University of Cincinnati Medical Center6 papers (2017–2025)José U. Scher · NYU Langone Health6 papers (2017–2025)Kristina Callis Duffin · University of Utah6 papers (2018–2025)Emmanuel During · Palo Alto University5 papers (2023–2024)Richard B. Warren · Novartis (Switzerland)5 papers (2020–2024)Laura C. Coates · Nuffield Orthopaedic Centre5 papers (2020–2025)Peter Foley · The University of Melbourne5 papers (2023–2024)Vibeke Strand · Stanford University5 papers (2023–2025)Alexis Ogdie · Hospital of the University of Pennsylvania5 papers (2017–2025)Marius Ardeleanu · Rockefeller University5 papers (2023–2024)Mark Lebwohl · Mount Sinai Hospital5 papers (2018–2024)Albert S. Chiou · Palo Alto University5 papers (2023–2024)Jashin J. Wu · Novartis (Switzerland)4 papers (2018–2024)Iain B. McInnes · University of Glasgow4 papers (2020–2025)Andrew Blauvelt · Trinity College Dublin4 papers (2018–2025) · 4 papers (2023–2023)Zafer E. Ozturk · Novartis (Switzerland)4 papers (2023–2024)